Revenue: As of FY2025 Q4, the actual value is USD 75.1 M, beating the estimate of USD 71.4 M.EPS: As of FY2025 Q4, the actual value is USD -1.65, missing the estimate of USD -0.82.EBIT: As of FY2025 Q4, the actual value is USD -9.223 M.<h3>Fourth Quarter 2025 Financial and Operational Metrics</h3><ul><li>Revenue: Medifast, Inc. (快验保) reported revenue of $75.1 million, a decrease of 36.9% compared to $119.0 million in the fourth quarter of 2024.</li><li>Active Earning Coaches: The total number of active earning coaches decreased by 40.6% to 16,100, down from 27,100 in the fourth quarter of 2024.</li><li>Revenue per Active Earning Coach: The average revenue per active earning coach increased by 6.2% to $4,664, compared to $4,391 in the fourth quarter of 2024.</li><li>Net Loss: Net loss was -$18.1 million, which includes a $12.1 million non-cash valuation allowance on deferred tax balance, compared to a net income of $0.8 million in the fourth quarter of 2024.</li><li>Gross Profit: Gross profit decreased by 40.9% to $52.1 million from $88.2 million in the fourth quarter of 2024, with gross profit as a percentage of revenue at 69.4% compared to 74.1% in the prior-year period.</li><li>Selling, General, and Administrative Expenses (SG&amp;A): SG&amp;A decreased by 31.5% to $59.9 million from $87.5 million in the fourth quarter of 2024, but increased as a percentage of revenue to 79.8% from 73.5%.</li><li>Loss from Operations: Loss from operations was -$7.8 million, or -10.4% as a percentage of revenue, compared to income from operations of $0.7 million, or 0.6% as a percentage of revenue, in the fourth quarter of 2024.</li><li>Other Income: Other income increased by 151.1% to $1.4 million from $0.6 million in the fourth quarter of 2024.</li><li>Effective Tax Rate: The effective tax rate was -183.9% for the fourth quarter of 2025, primarily due to establishing a $12.1 million non-cash valuation allowance, compared to 37.3% in the prior-year period.</li></ul><h3>Full Year 2025 Financial Metrics</h3><ul><li>Revenue: For the full year 2025, revenue decreased by 36.0% to $385.8 million compared to $602.5 million in 2024.</li><li>Net Loss: Net loss was -$18.7 million, including a $12.1 million non-cash valuation allowance, compared to a net income of $2.1 million in 2024.</li><li>Cash, Cash Equivalents, and Investment Securities: As of December 31, 2025, Medifast, Inc. (快验保) had $167.3 million in cash, cash equivalents, and investment securities, compared to $162.3 million in cash and cash equivalents at December 31, 2024, with no interest-bearing debt.</li><li>Working Capital: Working capital was $158.7 million as of December 31, 2025, compared to $150.2 million at December 31, 2024.</li><li>Gross Profit: Gross profit was $275.187 million for the full year 2025, compared to $444.623 million in 2024.</li><li>Selling, General, and Administrative Expenses (SG&amp;A): SG&amp;A was $289.400 million for the full year 2025, compared to $441.745 million in 2024.</li><li>Loss from Operations: Loss from operations was -$14.213 million for the full year 2025, compared to income from operations of $2.878 million in 2024.</li><li>Other Income: Other income was $8.574 million for the full year 2025, compared to $0.909 million in 2024.</li><li>Provision for Income Taxes: Provision for income taxes was $13.033 million for the full year 2025, compared to $1.696 million in 2024.</li></ul><h3>Outlook</h3>Medifast, Inc. (快验保) expects first quarter 2026 revenue to be in the range of $65 million to $80 million, with a projected loss per share ranging from -$0.15 to -$0.70. For the full year 2026, the company anticipates revenue between $270 million and $300 million and a loss per share ranging from -$1.55 to -$2.75.

Medifast | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 75.1 M